Chimeric antibody with specificity to human B cell surface antigen

• US 5,500,362 A
• Filed: 03/05/1991
• Issued: 03/19/1996
• Est. Priority Date: 01/08/1987
• Status: Expired due to Term

• Current Assignee: Royalty Pharma Finance Trust
• Original Assignee: Xoma Corp.
• Inventors: Liu, Alvin Y., Ledbetter, Jeffrey A., Robinson, Randy R.
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US07/665,939
• Time in Patent Office: 1,841 Days
• Field of Search: 435/7.23, 435/7.24, 435/70.21, 435/172.2, 435/240.27, 436/548, 436/813, 530/387.3, 530/388.73, 530/391.3, 530/391.7, 935/15, 424/85.8, 424/85.91, 424/85.8, 424/133.1, 424/153.1, 424/155.1
• US Class Current: 435/7.23
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 47/6877 the antibody being an immunoglobulin containing regions, domains or residues from different species
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/462 Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/40 containing a tag for immunodetection, or an epitope for immunisation

Abstract

The present invention relates to a chimeric IgG1 antibody molecule comprising two heavy chains and two light chains, each of the chains comprising a human constant region and a variable region, said antibody having specificity for the antigen bound by the 2H7 murine monoclonal antibody. The invention also relates to the increased ADCC and CDC cytolytic activities of the chimeric antibody, methods of production by recombinant DNA techniques, and uses.

Claims

1. A chimeric IgG1 antibody molecule comprising two heavy chains and two light chains, each of said chains comprising a human constant region and a variable region, said chimeric antibody being produced in a eukaryotic host, and having specificity for the antigen bound by the antibody produced by hybridoma HB9303 as deposited with the ATCC and said chimeric antibody having cytolytic activity, wherein said cytolytic activity is antibody-dependent cellular cytotoxicity or complement-dependent cytolysis.

2. The chimeric antibody of claim 1 wherein said cytolytic activity is antibody-dependent cellular cytotoxicity.

3. The chimeric antibody of claim 1 wherein said cytolytic activity is complement-dependent cytolysis.

4. The chimeric antibody of claim 1 wherein said host is a yeast cell.

5. The chimeric antibody of claim 1 wherein said host is a mammalian cell.

6. A method for killing cells bearing the antigen bound by the antibody produced by hybridoma HB9303 as deposited with the ATCC comprising:

(a) contacting said cells with the antibody of claim 1; and

(b) allowing said killing to occur,

wherein said killing occurs by antibody-dependent cellular cytotoxicity or complement-mediated lysis of said cells.

7. The method of claim 6 wherein said killing occurs by complement-mediated lysis of said cells.

8. The method of claim 6 wherein said killing occurs by antibody-dependent cellular cytotoxicity.

9. A chimeric antibody specific for the B cell Bp35 antigen, comprising a human constant region and a variable region, produced by hybridoma HB9303 as deposited with the ATCC.